Missouri Legislator Files Measure to Decriminalize
Post# of 160
(Total Views: 238)
Posted On: 03/14/2022 4:47:11 PM
Missouri Legislator Files Measure to Decriminalize Psychedelics
Last week, a Missouri legislator filed a measure that would legalize an extensive range of psychedelic drugs for therapeutic use and decriminalize low-level possession in the state. The measure was sponsored by Republican lawmaker, Rep. Tony Lovasco. It is the latest example of psychedelic reforms being introduced in states that are traditionally conservative.
The measure would provide patients suffering from conditions such as post-traumatic stress disorder treatment-resistant depression and other terminal illnesses with access to a wider range of substances including ibogaine, mescaline, DMT and psilocybin in a clinical setting. Patients will be allowed to access this treatment option at residential care facilities, hospice care sites, a caregiver’s or patient’s residence and in certified health facilities.
The measure would also give qualified doctors who make recommendations for natural medicine to eligible patients legal protections from being prosecuted. It stipulates that the medical use of natural medicine by an eligible caregiver or patient in compliance with set guidelines wouldn’t be subject to civil or criminal liability under the laws of the state.
The measure would also decriminalize the possession of up to four grams of psychedelic drugs and such possession would be punishable by a $500 fine but no jail time. However, possession of more than four grams of drugs would carry a penalty of a $2,000 fine and one year in jail.
Earlier in January, another legislator in Missouri also introduced a measure to give residents with severe ailments legal access to an extensive range of psychedelics, including LSD, ibogaine and psilocybin, under the state’s right-to-try law.
Psychedelics reform is also advancing in other states across the country. For instance, legislators in Utah recently forwarded a measure to their governor that would establish a task force to conduct research on psychedelic drugs and make recommendations on regulations for the lawful use of these drugs. Legislators in Oklahoma also passed a measure in committee last week that would promote research into the therapeutic potential of psilocybin and decriminalize the low-level possession of the psychedelic.
Additionally, a Senate committee in Oregon also advanced a resolution that would ensure that equity was integrated into the state’s psilocybin therapy program, which was approved in 2002 by voters and is currently being implemented. Furthermore, a Senate committee in Hawaii passed a measure that would establish a working group in the state which would carry out research on the therapeutic benefits of hallucinogenic mushrooms and develop a plan that would make psilocybin accessible for medical use by individuals aged 21 and above.
As more cities and states enact psychedelic policy reform, companies such as Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) will feel vindicated that their projections about the future of the psychedelics sector was spot on.
NOTE TO INVESTORS: The latest news and updates relating to Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are available in the company’s newsroom at https://ibn.fm/MYCOF
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Last week, a Missouri legislator filed a measure that would legalize an extensive range of psychedelic drugs for therapeutic use and decriminalize low-level possession in the state. The measure was sponsored by Republican lawmaker, Rep. Tony Lovasco. It is the latest example of psychedelic reforms being introduced in states that are traditionally conservative.
The measure would provide patients suffering from conditions such as post-traumatic stress disorder treatment-resistant depression and other terminal illnesses with access to a wider range of substances including ibogaine, mescaline, DMT and psilocybin in a clinical setting. Patients will be allowed to access this treatment option at residential care facilities, hospice care sites, a caregiver’s or patient’s residence and in certified health facilities.
The measure would also give qualified doctors who make recommendations for natural medicine to eligible patients legal protections from being prosecuted. It stipulates that the medical use of natural medicine by an eligible caregiver or patient in compliance with set guidelines wouldn’t be subject to civil or criminal liability under the laws of the state.
The measure would also decriminalize the possession of up to four grams of psychedelic drugs and such possession would be punishable by a $500 fine but no jail time. However, possession of more than four grams of drugs would carry a penalty of a $2,000 fine and one year in jail.
Earlier in January, another legislator in Missouri also introduced a measure to give residents with severe ailments legal access to an extensive range of psychedelics, including LSD, ibogaine and psilocybin, under the state’s right-to-try law.
Psychedelics reform is also advancing in other states across the country. For instance, legislators in Utah recently forwarded a measure to their governor that would establish a task force to conduct research on psychedelic drugs and make recommendations on regulations for the lawful use of these drugs. Legislators in Oklahoma also passed a measure in committee last week that would promote research into the therapeutic potential of psilocybin and decriminalize the low-level possession of the psychedelic.
Additionally, a Senate committee in Oregon also advanced a resolution that would ensure that equity was integrated into the state’s psilocybin therapy program, which was approved in 2002 by voters and is currently being implemented. Furthermore, a Senate committee in Hawaii passed a measure that would establish a working group in the state which would carry out research on the therapeutic benefits of hallucinogenic mushrooms and develop a plan that would make psilocybin accessible for medical use by individuals aged 21 and above.
As more cities and states enact psychedelic policy reform, companies such as Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) will feel vindicated that their projections about the future of the psychedelics sector was spot on.
NOTE TO INVESTORS: The latest news and updates relating to Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are available in the company’s newsroom at https://ibn.fm/MYCOF
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
(0)
(0)